



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Selnoflast

Cat. No.:	HY-132831
CAS No.:	2260969-36-4
Molecular Formula:	C ₂₀ H ₂₉ N ₃ O ₃ S
Molecular Weight:	391.53
Target:	NOD-like Receptor (NLR)
Pathway:	Immunology/Inflammation
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 5 mg/mL (12.77 mM; ultrasonic and adjust pH to 8 with 1M NaOH)
 1M NaOH : 3.33 mg/mL (8.51 mM; adjust pH to 12 with 1M NaOH)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.5541 mL	12.7704 mL	25.5408 mL
	5 mM		0.5108 mL	2.5541 mL	5.1082 mL
	10 mM		0.2554 mL	1.2770 mL	2.5541 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Selnoflast (RO-7486967) Formerly known as Somalix/RG6418/IZD334, Selnoflast is an orally available inhibitor of NLRP3. Selnoflast is used in research into systemic inflammation, such as ulcerative colitis and chronic obstructive pulmonary disease^{[1][2]}.

IC₅₀ & Target

NLRP3

CUSTOMER VALIDATION

- Cell Chem Biol. 2023 Oct 12:S2451-9456(23)00335-5.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29.
- [2]. Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13(11):e1471.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA